Oramed Pharmaceuticals (ORMP) Competitors $2.26 -0.04 (-1.74%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ORMP vs. ETTX, MITO, VALN, AMLX, DNA, ALEC, QTTB, CTNM, CYRX, and KMDAShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), Valneva (VALN), Amylyx Pharmaceuticals (AMLX), Ginkgo Bioworks (DNA), Alector (ALEC), Q32 Bio (QTTB), Contineum Therapeutics (CTNM), Cryoport (CYRX), and Kamada (KMDA). Oramed Pharmaceuticals vs. Entasis Therapeutics Stealth BioTherapeutics Valneva Amylyx Pharmaceuticals Ginkgo Bioworks Alector Q32 Bio Contineum Therapeutics Cryoport Kamada Entasis Therapeutics (NASDAQ:ETTX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Which has preferable valuation and earnings, ETTX or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntasis Therapeutics$7M14.97-$47.14M-$1.12-1.96Oramed Pharmaceuticals$1.34M67.99$5.53M$0.514.43 Do institutionals & insiders believe in ETTX or ORMP? 6.9% of Entasis Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 6.5% of Entasis Therapeutics shares are held by insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend ETTX or ORMP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to ETTX or ORMP? In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Entasis Therapeutics. MarketBeat recorded 1 mentions for Oramed Pharmaceuticals and 0 mentions for Entasis Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 0.75 beat Entasis Therapeutics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Entasis Therapeutics Neutral Oramed Pharmaceuticals Positive Is ETTX or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -7.28% beat Entasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entasis TherapeuticsN/A -145.48% -103.75% Oramed Pharmaceuticals N/A -7.28%-6.22% Does the MarketBeat Community prefer ETTX or ORMP? Oramed Pharmaceuticals received 223 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 73.84% of users gave Oramed Pharmaceuticals an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote. CompanyUnderperformOutperformEntasis TherapeuticsOutperform Votes9664.86% Underperform Votes5235.14% Oramed PharmaceuticalsOutperform Votes31973.84% Underperform Votes11326.16% Which has more volatility and risk, ETTX or ORMP? Entasis Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. SummaryOramed Pharmaceuticals beats Entasis Therapeutics on 14 of the 15 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.72M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio4.434.8389.0213.30Price / Sales67.99372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book0.597.876.085.74Net Income$5.53M$153.61M$119.07M$225.93M7 Day Performance-3.21%-2.00%-1.84%-1.32%1 Month Performance-3.83%-7.47%-3.65%0.60%1 Year Performance5.61%31.80%31.62%26.23% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.478 of 5 stars$2.26-1.7%N/A+4.6%$92.72M$1.34M4.4310News CoverageETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651MITOStealth BioTherapeuticsN/A$0.32flatN/AN/A$23.54M$21.09M-0.6229VALNValneva2.2761 of 5 stars$4.67+2.4%$18.50+296.1%-62.1%$370.49M$165.52M0.00700AMLXAmylyx Pharmaceuticals4.3606 of 5 stars$5.23+0.2%$11.43+118.5%-59.5%$358.51M$196.49M-1.37200Analyst UpgradeDNAGinkgo Bioworks1.1347 of 5 stars$6.36-1.4%$4.58-28.1%N/A$358.46M$251.46M0.001,218Short Interest ↓ALECAlector4.4456 of 5 stars$3.64-5.7%$20.67+468.5%-26.1%$355.99M$61.51M-2.23270Positive NewsQTTBQ32 Bio1.6079 of 5 stars$27.28-6.2%$72.33+165.2%N/A$354.34M$1.16M0.0039CTNMContineum Therapeutics1.6382 of 5 stars$13.65+2.6%$29.25+114.3%N/A$342.85M$50M0.0031CYRXCryoport2.7225 of 5 stars$6.57-5.2%$12.50+90.3%-52.6%$342.80M$233.26M0.001,170Insider TradeKMDAKamada3.8063 of 5 stars$5.82-1.5%$14.50+149.1%+23.3%$339.70M$142.52M20.79360Analyst Revision Related Companies and Tools Related Companies Entasis Therapeutics Competitors Stealth BioTherapeutics Competitors Valneva Competitors Amylyx Pharmaceuticals Competitors Ginkgo Bioworks Competitors Alector Competitors Q32 Bio Competitors Contineum Therapeutics Competitors Cryoport Competitors Kamada Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORMP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
